Provided by Tiger Trade Technology Pte. Ltd.

NLS Pharmaceutics Ltd.

0.7620
0.0000
Volume:- -
Turnover:- -
Market Cap:3.97M
PE:- -
High:0.7620
Open:0.7620
Low:0.7620
Close:0.7620
52wk High:30.80
52wk Low:0.7620
Shares:5.21M
Float Shares:3.42M
Volume Ratio:3.99
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.6288
ROE:-862.92%
ROA:-75.98%
PB:1.41
PE(LYR):-0.29

Loading ...

NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board

Reuters
·
Nov 06, 2025

NLS Pharmaceutics and Kadimastem merge to form NewcelX

Reuters
·
Nov 04, 2025

NewcelX Unveils Strategic Roadmap Post-Merger with NLS Pharmaceutics

TIPRANKS
·
Nov 03, 2025

NLS Pharmaceutics AG Releases Investor Presentation Document

Reuters
·
Nov 03, 2025

NLS Pharmaceutics AG trading halted, news pending

TIPRANKS
·
Oct 31, 2025

BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of Merger

Reuters
·
Oct 31, 2025

NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX

TIPRANKS
·
Oct 31, 2025

Press Release: NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

Dow Jones
·
Oct 31, 2025

NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger

TIPRANKS
·
Oct 29, 2025

NLS Pharmaceutics and Kadimastem Secure Continued BIRD Foundation Support Following Merger

Reuters
·
Oct 29, 2025

NLS Pharmaceutics: Following Merger Between Co and Kadimastem,Combined Co Will Continue to Advance Itol-102 Program

THOMSON REUTERS
·
Oct 29, 2025

BRIEF-Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem

Reuters
·
Oct 29, 2025

NLS Pharmaceutics - Reverse Split Effective in Switzerland on October 30, 2025

THOMSON REUTERS
·
Oct 29, 2025

NLS Pharmaceutics - Common Shares to Trade on Nasdaq as Ncel Under New Name Newcelx Ltd

THOMSON REUTERS
·
Oct 29, 2025

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection With Proposed Merger With Kadimastem

THOMSON REUTERS
·
Oct 29, 2025

Press Release: NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

Dow Jones
·
Oct 29, 2025

NLS Pharmaceutics and Kadimastem Set October 30 Closing for Merger and Nasdaq Listing as NewCelX

Reuters
·
Oct 29, 2025

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration Between Kadimastem and Targetgene to Advance Next-Generation Gene-Edited Cell Therapies

THOMSON REUTERS
·
Oct 27, 2025

Press Release: NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

Dow Jones
·
Oct 27, 2025

Press Release: NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

Dow Jones
·
Oct 23, 2025